The company has landed a lucrative flu-vaccine contract with the U.S. government. It's worth $97 million over the first three years, and it can be extended for an additional two years, for a total contract value of $179.1 million. The technology could prove to be a lifesaver.
Though the threat of H1N1 infection remains, the World Health Organization has declared an end to the Swine Flu pandemic, citing "pure good luck" to explain why the disease wasn't as lethal as feared.
Here's a roundup of some of the major news moving stocks in the pharmaceutical industry: GlaxoSmithKline shares fell after the FDA warned against long-term use of asthma treatments Advair and Serevent. Meanwhile, a new study shows Novavax's vaccine against swine flu is effective.
Investors who've increased their risk appetite should take note of the reward potential in the biotech sector. Capitalizing on this trend is tricky, but it can be lucrative. Keep an eye on these five notable names that now trade for less than five bucks.
A biotech with a novel method of making vaccines, has a promising swine flu drug. So far, so good, but it's hardly a lock